Lisa Sequino Appointed President, Makeup Brand Cluster, The Estée Lauder Companies
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Lisa Sequino as the new President,Makeup Brand Cluster, responsible for leading the strategic direction and global growth of makeup, and overseeing the company’s portfolio of makeup brands, including M·A·C, Bobbi Brown, Too Faced, Smashbox and GLAMGLOW. Ms. Sequino will report to Jane Hertzmark Hudis, Executive Vice President, Chief Brand Officer and will be effective in the role as of June 9, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529597946/en/
A respected leader with more than two decades of experience in the beauty industry, Ms. Sequino returns to The Estée Lauder Companies with a distinctive blend of deep institutional knowledge and proven success as a CEO. In her new role, she will be responsible for accelerating innovation and makeup trends, step-changing consumer recruitment and enhancing local relevance. Her appointment reflects the company’s continued investment in strengthening its makeup category and unlocking long-term opportunity.
“We are thrilled to welcome Lisa as the new leader of our makeup cluster,” said Jane Hertzmark Hudis. “She is a powerful leader with a strong record of driving brand and business results. Her unique combination of strategic and conceptual thinking, entrepreneurial mindset and operational excellence makes her exceptionally well-suited to fast track our makeup cluster into its next phase of growth. Under Lisa’s leadership, we are focused on winning with today’s makeup consumer across generations, geographies and channels.”
With nine years of experience at The Estée Lauder Companies in senior roles across both global and North America businesses, Ms. Sequino’s extensive familiarity with the company and its brands will enable her to quickly accelerate momentum across the makeup brand cluster. She served as Senior Vice President and General Manager of Estée Lauder – North America, where she led the go-to-market strategy and execution for the company’s flagship brand in its home region. She later advanced to Senior Vice President, Brands – North America, where she oversaw a multi-brand portfolio across skincare, makeup, and fragrance, and was responsible for optimizing brand synergies and accelerating execution across categories and channels in the region.
Following her impactful tenure at the company, Ms. Sequino served as CEO of JLo Beauty, Jennifer Lopez’s beauty brand, and most recently, was CEO of Supergoop!, where she fostered an indie and digital-first mindset to expand its global footprint. Under her leadership, Supergoop! captured emerging trends to launch innovative products for the brand – including tinted moisturizers, lip balms, and setting powders – that redefined the category for Supergoop! and broadened consumer usage occasions.
“I’m excited to return to The Estée Lauder Companies to help drive the next chapter of growth in the makeup category,” said Lisa Sequino. “There’s tremendous opportunity to reach new makeup consumers globally by accelerating innovation and trends, fast-tracking consumer acquisition across channels, driving digital and social media, and assuring local relevance to win with today’s makeup consumer. I look forward to partnering with the incredible teams behind M·A·C, Bobbi Brown, Too Faced, Smashbox, and GLAMGLOW to unlock new opportunities, scale impact, and drive meaningful business results.”
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement the Company’s strategy, including Beauty Reimagined and the profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent filings with the Securities and Exchange Commission. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529597946/en/
Contacts
Media Relations:
Meridith Webster
mwebster@estee.com
Investor Relations:
Rainey Mancini
rmancini@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom